Sanofi (SNY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, this is Thomas Guslaten from the Tenofi IR team. Welcome to the first quarter 2026 conference call for investors and analysts. As usual, you will find the slides on tenofi.com. Please turn to slide number three. Here we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risk and uncertainties that may cause actual results to differ materially. We encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our new Form 20F on file with the U.S. SEC since February and our French Universal Registration Document for description of these risk factors. As usual, we'll be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in millions of euros and for the first quarter, unless stated otherwise. Please turn to slide number four. First, we have a short presentation, then we'll take your questions. We aim at keeping it all to one hour, including the questions. We are mindful that other companies are also reporting today. For the Q&A, we have Manuela and Thomas to cover our global businesses, as well as Roy, our General Counsel, and Brendan, Head of Manufacturing and Supply. You can participate in this Q&A in two ways. Either raise your hand and Zoom, or submit your question using the Q&A feature. With that, I now hand you over to Olivier, our Interim CEO. Hello, everyone, and thank you for joining our conference call. As Thomas mentioned, I'm the Interim CEO before our new CEO, Belen Garrigo, joined Sanofi in May after next week's Annual General Meeting. Before we get started, I also want to thank Paul Hudson for his work as CEO from 2019 to 2...